News articles about Valeritas (NASDAQ:VLRX) have been trending somewhat positive on Saturday, Accern Sentiment reports. Accern rates the sentiment of media coverage by monitoring more than 20 million news and blog sources in real time. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Valeritas earned a coverage optimism score of 0.10 on Accern’s scale. Accern also assigned headlines about the company an impact score of 44.8574313221501 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the near future.
NASDAQ:VLRX traded up $0.06 during mid-day trading on Friday, reaching $1.42. The company’s stock had a trading volume of 326,663 shares, compared to its average volume of 366,431. The company has a current ratio of 2.56, a quick ratio of 1.80 and a debt-to-equity ratio of -2.57. Valeritas has a twelve month low of $1.19 and a twelve month high of $7.20. The firm has a market cap of $30.45 million, a price-to-earnings ratio of -0.17 and a beta of 4.32.
Valeritas (NASDAQ:VLRX) last issued its quarterly earnings results on Wednesday, May 9th. The company reported ($1.72) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($2.13) by $0.41. Valeritas had a negative return on equity of 1,768.69% and a negative net margin of 225.97%. The firm had revenue of $6.08 million for the quarter, compared to analyst estimates of $6.00 million. research analysts forecast that Valeritas will post -6.67 earnings per share for the current fiscal year.
A number of analysts have issued reports on the company. ValuEngine raised Valeritas from a “sell” rating to a “hold” rating in a research note on Wednesday, May 2nd. Cowen lowered Valeritas from an “outperform” rating to a “market perform” rating in a research note on Wednesday, March 28th.
In other news, insider John Edward Timberlake acquired 22,500 shares of the business’s stock in a transaction dated Wednesday, April 25th. The shares were bought at an average cost of $1.67 per share, for a total transaction of $37,575.00. The purchase was disclosed in a document filed with the SEC, which is available through the SEC website. Also, Director Joseph M. Mandato acquired 20,000 shares of the business’s stock in a transaction dated Thursday, May 10th. The stock was purchased at an average price of $1.63 per share, for a total transaction of $32,600.00. The disclosure for this purchase can be found here. Over the last 90 days, insiders bought 47,500 shares of company stock worth $78,275. Company insiders own 1.20% of the company’s stock.
Valeritas Holdings, Inc, a commercial-stage medical technology company, focuses on the development and commercialization of technologies to treat patients with Type 2 diabetes in the United States and China. It offers V-Go, a wearable insulin delivery device for basal-bolus therapy. The company also develops h-Patch, a controlled delivery technology platform; Mini-Ject technology for needle-free injection systems; and Micro-Trans technology for microneedle design, fabrication, and drug delivery.
Receive News & Ratings for Valeritas Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Valeritas and related companies with MarketBeat.com's FREE daily email newsletter.